ALGS — Aligos Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $39.34m
- -$73.17m
- $15.53m
- 12
- 41
- 69
- 35
Annual cashflow statement for Aligos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.3 | -109 | -128 | -96 | -87.7 |
| Depreciation | |||||
| Non-Cash Items | -0.473 | 15.5 | 14.3 | 15.9 | 16.6 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.67 | 16.1 | -4.65 | -1.55 | -9.53 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -46.8 | -74.3 | -116 | -79.4 | -79 |
| Capital Expenditures | -2.79 | -2.06 | -0.892 | -0.943 | -0.019 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 9.58 | 34.8 | 3.91 | -25.4 | 45 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 6.79 | 32.8 | 3.02 | -26.3 | 45 |
| Financing Cash Flow Items | — | -4.12 | -0.875 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 85.5 | 192 | 78.7 | 0.164 | 88.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 45.6 | 151 | -34 | -106 | 54.3 |